CAMP4 on a new class of ASO in gene under expression

SYNGAP1-related disorder negatively impacts synaptic signalling during critical periods of brain development, leading to a range of cognitive, epileptic, behavioural, and motor symptoms.

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Kelly Gold, CFO of CAMP4 Therapeutics, about antisense oligonucleotides (or ASOs) - medicines designed to selectively restore natural protein production in diseases caused by gene under-expression.

Gold discusses the space and CAMP4’s CMP-002 study, targeting the regRNA-associated SYNGAP1 gene. You can listen to episode 269 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.